SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

Strona główna・Stock List・Pharming Group NV

P
Pharming Group NV

Closed

1.418 4.19

Buy Sell

Overview

Share price change

24h

Current

Min

1.357

Max

1.422

Key metrics
By Trading Economics
Income	2.9M 7.5M
Sales	4.1M 97M
EPS	0.009
Profit margin	7.758
Employees	404

Market Stats
By TradingEconomics
Market Cap	-51M 946M
Previous open	-2.77
Previous close	1.418

Pharming Group NV Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 gru 2025, 20:41 UTC

Earnings

Major Market Movers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 gru 2025, 18:14 UTC

Acquisitions, Mergers, Takeovers

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 gru 2025, 17:43 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 gru 2025, 17:01 UTC

Earnings

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 gru 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 gru 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4 gru 2025, 21:37 UTC

Earnings

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 gru 2025, 21:36 UTC

Earnings

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 gru 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 gru 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 gru 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 gru 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 gru 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 gru 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 gru 2025, 16:33 UTC

Market Talk

Earnings

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Comparison

Price change

Pharming Group NV Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Pharming Group NV - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.